Corcoran Gavin 4
4 · Axovant Gene Therapies Ltd. · Filed Jun 15, 2020
Insider Transaction Report
Form 4
Corcoran Gavin
EVP of R&D
Transactions
- Award
Common Shares
2020-06-12+16,002→ 16,002 total - Tax Payment
Common Shares
2020-06-12$3.46/sh−6,211$21,490→ 9,791 total - Disposition to Issuer
Restricted Stock Units
2020-06-12−16,002→ 16,001 total→ Common Shares (16,002 underlying)
Footnotes (3)
- [F1]The shares were sold on behalf of the Reporting Person in the open market to cover withholding taxes relating to the settlement of the vested restricted stock units.
- [F2]Each restricted stock unit represents the right to receive one share of the Issuer's common stock. 50% of the common shares underlying the restricted stock units vested on January 31, 2020 but settlement of such portion of the restricted stock units was delayed until transactions acceptable under the Issuer's insider trading policy were permitted
- [F3]50% of the common shares underlying the restricted stock units vest on January 31, 2020 and the remainder vest on July 31, 2020, subject to the Reporting Person providing continuous service to the Issuer through each such date.